This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Safety & Efficacy Testing Solutions
Alcyomics’s innovative assays have been developed using human cells and tissues to give an accurate human response. Our unique safety and efficacy testing platforms can add value from initial drug discovery to product development including early discovery, pre and post clinical application or product launch.
Not only can our assays significantly improve the testing process making it faster, cheaper, and more effective, but they also can improve the success rate in drug discovery with the development of new biomarkers, precise drug targets and new preclinical models that better recapitulate in vivo human biology and microenvironmental factors.
In addition to the clear advantage of providing cost reduction in clinical drug development, Alcyomics helps our customers reduce the use of animal testing models in the key stages of drug development thereby further reducing costs, and improving speed to market while providing a better return on investment.
In addition to the clear advantage of providing cost reduction in clinical drug development, Alcyomics helps our customers reduce the use of animal testing models in the key stages of drug development thereby further reducing costs, and improving speed to market while providing a better return on investment.
Advantages of Alcyomics technology:
Only human tissue based assay on the market which accurately predicts clinical response
Enables company’s to assess drugs for potential failure prior to expensive further pre-clinical animal model testing
Assays give insight to mode of action and knowledge into potential drug failure and preventative measures
More specific, shows actual tissue damage which may be caused by the drugs – toxicity, adverse immune reactions, allergy, hypersensitivity
Get in touchImmunotoxicity (Skimune®)
Testing Platform
Solution Description:
Preclinical safety and efficacy testing of drugs as “first in man studies”, sensitisation testing of chemicals and cosmetics, safety and efficacy testing of cellular therapies. Human in vitro tests as alternative to animal models.
Key Capabilities:
Predicts adverse immune responses to compounds demonstrating if the compound has the potential to activate the human immune system , with DC/T cell activation, cytokine release and histopathology associated with allergy, hypersensitivity or sensitisation responses.
Benefits:
Rapid identification of adverse immune responses not identified in animal models
Human model, more sensitive and more predictive of clinical outcome than animal models
Uses human cells and tissue; incorporates multiple key events of the adverse outcome pathway (AOP)
Can test a range of different compounds e.g. small molecule drugs, monoclonal antibodies, cellular therapies, raw materials, end products and more
Incorporates. T-cell proliferation responses, cytokine responses, skin explant histopathology
Highly predictive e.g. tested >200 compounds and shows 80-90% accuracy
Highly customised assay
Get in touchCell Culturing 2D Platform
Solution Description:
Higher throughput pre-clinical sensitisation testing of chemicals, biologics, and cosmetics. Outsourcing partner for molecular analysis, large range of molecular techniques available, cell culture is our core expertise.
Key Capabilities:
Cell culture expertise, cell isolation, cell line development, iImmunohistochemistry, immunocytochemistry, ELISA, western blotting, multiplex cytokine analysis, T-cell proliferation assays, RNA extraction, RTPCR, RNA sequencing.
Benefits:
Rapid identification of adverse immune responses not identified in animal models
Human model, more sensitive and more predictive of clinical outcome than animal models
Uses human cells and tissue; incorporates multiple key events of the adverse outcome pathway (AOP)
Can test a range of different compounds e.g. small molecule drugs, monoclonal antibodies, cellular therapies, raw materials, end products and more
Incorporates. T-cell proliferation responses, cytokine responses, skin explant histopathology
Highly predictive e.g. tested >200 compounds and shows 80-90% accuracy
Highly customised assay
Get in touchTissue Engineering 3D Platform
Solution Description:
Development of complex and functional high-throughput in-vitro 3D tissue models for replicating disease states and high-throughput molecule screening.
Key Capabilities:
Can develop and optimise tailor made 3D models for for in vitro research applications e.g. wound healing, anti-ageing.
Benefits:
Gel-free 3D models allow cells to manufacture and regulate their own extra cellular matrix (ECM)
Can use cells from non-animal sources including iPSC derived lineages to develop fully humanised models
Offers 96 well format high-throughput screening
Can be bioprinted for improved throughput and reproducibility
Can develop physiological tissue which replicate disease states e.g. Atopic dermatitis, osteoarthritis, innervated skin
Assays can be autologous (cells or tissues obtained from the same individual) and incorporate immune cells
Can perform RNA extraction, RTPCR and RNA sequencing analysis
Get in touchOECD Guideline Testing Platform
Solution Description:
Standardised human epidermal skin equivalent for irritation and corrosivity testing applications.
Key Capabilities:
Capable of predicting skin irritation and chemical corrosivity inline with OECD test guidelines #431 and #439.
Benefits:
Full humanised system
Validated against OECD guidelines
Robust batch test procedures
Get in touch